Results 241 to 250 of about 93,268 (298)

The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding

open access: yesAnimal Research and One Health, EarlyView.
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang   +10 more
wiley   +1 more source

Differences in Tumor-Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma. [PDF]

open access: yesCancer Med
Toshida K   +13 more
europepmc   +1 more source

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma

open access: yes
American Journal of Hematology, EarlyView.
Léa Ousset   +2 more
wiley   +1 more source

A Mouse Model of Depression‐Tumor Multimorbidity Reveals the Mechanism of Tumor Growth Accelerated by Depression

open access: yesAnimal Research and One Health, EarlyView.
Depression accelerates tumor growth by dysregulation of tumor immune microenvironment. (A) Modeling methods: Subcutaneous tumor models were established under chronic unpredictable mild stress conditions, including cold swimming, physical restraint, and food/water deprivation, leading to increased tumor growth.
Yakun Ren   +6 more
wiley   +1 more source

An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers. [PDF]

open access: yesOral Oncol
Xirou V   +13 more
europepmc   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava   +8 more
wiley   +1 more source

Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy. [PDF]

open access: yesBreast Cancer
Nagahashi M   +16 more
europepmc   +1 more source

TWEAK/Fn14 Signaling Drives Oxidative Cardiac Injury in Systemic Lupus Erythematosus: Evidence From Patient Biomarker Studies, Lupus Mouse Models, and Cardiomyocyte Assays

open access: yesArthritis &Rheumatology, EarlyView.
Objective Cardiac involvement is a major cause of morbidity in systemic lupus erythematosus (SLE). Tumor necrosis factor–like weak inducer of apoptosis (TWEAK) is elevated in SLE, but its contribution to lupus‐associated cardiac injury is unclear. We investigated the role of TWEAK/fibroblast growth factor–inducible 14 (Fn14) signaling in SLE‐related ...
Yale Liu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy